Due to the precision-based cytotoxic nature of ADCs and tumour growth-suppressive effects consequential from endocrine modulation, concurrent use of an ADC and hormonal therapy is a promising new strategy for breast cancer treatment, particularly for hormone receptor-positive (HR+) subtypes. The gene discussed is NR4A1; the disease is neoplasm.